TaiGen Biopharmaceuticals Holdings Limited
4157
Rank in Stocks
#17250
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Share Price
$0.24661927
Last synced: 2026-11-10
Market Cap
$175.55M
Change (1 day)
-0.49%
Change (1 year)
-16.37%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade TaiGen Biopharmaceuticals Holdings Limited (4157)
Category
Healthcare
EPS for TaiGen Biopharmaceuticals Holdings Limited (4157)
EPS as of June 2026 TTM: $0.01
According to TaiGen Biopharmaceuticals Holdings Limited's latest financial reports, its current EPS (TTM) is $0.01. At the end of 2025 the company had an EPS of 0.00, equal to its 2024 EPS of 0.00.
EPS history for TaiGen Biopharmaceuticals Holdings Limited from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.01 | -225.00% |
| 2025 | 0.00 | -225.00% |
| 2024 | 0.00 | -125.81% |
| 2023 | $0.01 | -157.41% |
| 2022 | $-0.01 | -127.69% |
| 2021 | $0.04 | -295.98% |
| 2020 | $-0.02 | 45.26% |
| 2019 | $-0.01 | -12.74% |
| 2018 | $-0.02 | -144.73% |
| 2017 | $0.04 | -425.00% |
| 2016 | $-0.01 | -39.66% |
| 2015 | $-0.02 | -2.19% |
| 2014 | $-0.02 | -17.19% |
| 2013 | $-0.02 | -19.64% |
| 2012 | $-0.03 | -697.83% |
| 2011 | 0.00 | -100.12% |
| 2010 | $-3.81 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 230,194.12% |
US
|
|
| $-7.07 | -104,070.59% |
US
|
|
| $-5.29 | -77,894.12% |
AU
|
|
| $12.88 | 189,313.24% |
BE
|
|
| $21.56 | 316,958.82% |
NL
|
Questions about TaiGen Biopharmaceuticals Holdings Limited's earnings per share (EPS)
What is TaiGen Biopharmaceuticals Holdings Limited's earnings per share (EPS)?
TaiGen Biopharmaceuticals Holdings Limited's earnings per share (EPS) over the last twelve months is $0.01, as of Jun 2026.
What was TaiGen Biopharmaceuticals Holdings Limited's earnings per share (EPS) in 2025?
In 2025, TaiGen Biopharmaceuticals Holdings Limited's earnings per share (EPS) was 0.00, compared with 0.00 in 2024.
How has TaiGen Biopharmaceuticals Holdings Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, TaiGen Biopharmaceuticals Holdings Limited's earnings per share (EPS) was highest in 2021 ($0.04) and lowest in 2020 ($-0.02).
How does TaiGen Biopharmaceuticals Holdings Limited's earnings per share (EPS) compare with similar companies?
TaiGen Biopharmaceuticals Holdings Limited's earnings per share (EPS) ($0.01) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.